Table 3.

Efficacy outcome in the clinical study

Clinical outcome	Total (n=12)	SNK01 with GC (n=6)	SNK01 with C/GC (n=6)
Objective response rate	3 (25.0)	0 (0.0)	3 (50.0)
Disease control rate	12 (100)	6 (100)	6 (100)
Partial response	3 (25.0)	0 (0.0)	3 (50.0)
Stable disease	9 (75.0)	6 (100)	3 (50.0)
Progressive disease	0 (0.0)	0 (0.0)	0 (0.0)
Median progression-free survival (days)	143 (107–246)	143 (107–246)	145 (114–N/E)

Data are presented as number (percentage) or median (IQR).

.C/GC, cetuximab/GC; GC, gemcitabine/carboplatin.